arrow
J

Jianda Yuan

merck and co inc
H指数:49
被引数:2.6万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analysis of Plasma Epstein–Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122
2026-02-030
OAAI
Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma

用于预测局部晚期鼻咽癌短期疗效的深度学习模型

2024-09-010
PRE
Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629
2024-04-050
PRE
3D Segmentation of Necrotic Lung Lesions in CT Images Using Self-Supervised Contrastive Learning
2024-01-010
OA
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
2023-07-1014
PRE
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Pembrolizumab单药治疗与化疗在铂类预处理,复发或转移性鼻咽癌中的比较 (KEYNOTE-122): 一项开放标签,随机,III期试验

2023-03-0138
OAAI
KEYNOTE-495/KEYIMPACT: INTERIM ANALYSIS OF A RANDOMIZED, BIOMARKER-DIRECTED, PHASE 2 TRIAL OF PEMBROLIZUMAB-BASED COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
2021-11-106
OA
Current strategies for intratumoural immunotherapy-Beyond immune checkpoint inhibition

肿瘤内免疫治疗的当前策略-超越免疫检查点抑制

2021-11-0130
OA
KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer
2019-07-010
PRE
Immunotherapy of cancers comes of age
2017-08-2387
PREAI
Immunotherapy biomarkers 2016: overcoming the barriers

免疫疗法生物标志物2016: 克服障碍

2017-03-2121
OAAI
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

外周CD8效应记忆1型T细胞与ipilimumab治疗的IV期黑色素瘤患者的预后相关

2017-03-0183
OAAI
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET (vol 18, pg 883, 2012)
2016-12-0655
OAAI
Proportions of blood-borne Vδ1+and Vδ2+T-cells are associated with overall survival of melanoma patients treated with ipilimumab
2016-09-0160
OAAI
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma

淋巴细胞中的趋化因子受体模式反映了黑色素瘤的转移扩散

2016-02-0864
OA
Immune Monitoring Technology Primer: protein microarray ('seromics')
2016-01-1913
OAAI
Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts)

肿瘤浸润淋巴细胞 (til) 和外周血的综合免疫学评估,以评估早期乳腺癌 (ESBC) 患者 (pts) 中冷冻消融 (cryo) 加伊匹单抗 (ipi) 的协同作用

2015-05-011
PRE
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (vol 25, pg 399, 2015)

CTLA-4阻断的抗癌免疫疗法: IL-2受体的强制性贡献和可溶性CD25的负面预后影响 (第25卷,399页,2015页)

2015-03-03149
OAAI
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
2015-01-13149
OAAI